Ackerman William E, Zhang Xiaolan L, Rovin Brad H, Kniss Douglas A
Department of Obstetrics and Gynecology, Laboratory of Perinatal Research and Division of Maternal-Fetal Medicine, The Ohio State University, Columbus, OH 43210, USA.
Biol Reprod. 2005 Sep;73(3):527-35. doi: 10.1095/biolreprod.104.039032. Epub 2005 Apr 20.
Cyclooxygenase (COX) activity increases in the human amnion in the settings of term and idiopathic preterm labor, contributing to the generation of uterotonic prostaglandins (PGs) known to participate in mammalian parturition. Augmented COX activity is highly correlated with increased COX2 (also known as prostaglandin-endoperoxide synthase 2, PTGS2) gene expression. We and others have demonstrated an essential role for nuclear factor kappaB (NFkappaB) in cytokine-driven COX2 expression. Peroxisome proliferator-activated receptor gamma (PPARG), a member of the nuclear hormone receptor superfamily, has been shown to antagonize NFkappaB activation and inflammatory gene expression, including COX2. We hypothesized that PPARG activation might suppress COX2 expression during pregnancy. Using primary amnion and WISH cells, we evaluated the effects of pharmacological (thiazolidinediones) and putative endogenous (15-deoxy-Delta(12,14)-prostaglandin J2, 15d-PGJ2) PPARG ligands on cytokine-induced NFkappaB activation, COX2 expression, and PGE2 production. We observed that COX2 expression and PGE2 production induced by tumor necrosis factor alpha (TNF) were significantly abrogated by 15d-PGJ2. The thiazolidinediones rosiglitazone (ROSI) and troglitazone (TRO) had relatively little effect on cytokine-induced COX2 expression except at high concentrations, at which these agents tended to increase COX2 abundance relative to cells treated with TNF alone. Interestingly, treatment with ROSI, but not TRO, led to augmentation of TNF-stimulated PGE2 production. Mechanistically, we observed that 15d-PGJ2 markedly diminished cytokine-induced activity of the NFkappaB transcription factor, whereas thiazolidinediones had no discernable effect on this system. Our data suggest that pharmacological and endogenous PPARG ligands use both receptor-dependent and -independent mechanisms to influence COX2 expression.
在足月产和特发性早产情况下,人羊膜中的环氧化酶(COX)活性增加,这有助于产生已知参与哺乳动物分娩的子宫收缩性前列腺素(PGs)。COX活性增强与COX2(也称为前列腺素内过氧化物合酶2,PTGS2)基因表达增加高度相关。我们和其他人已经证明核因子κB(NFκB)在细胞因子驱动的COX2表达中起重要作用。过氧化物酶体增殖物激活受体γ(PPARG)是核激素受体超家族的成员,已被证明可拮抗NFκB激活和炎症基因表达,包括COX2。我们假设PPARG激活可能在怀孕期间抑制COX2表达。使用原代羊膜细胞和WISH细胞,我们评估了药理学(噻唑烷二酮类)和假定的内源性(15-脱氧-Δ12,14-前列腺素J2,15d-PGJ2)PPARG配体对细胞因子诱导的NFκB激活、COX2表达和PGE2产生的影响。我们观察到,15d-PGJ2可显著消除肿瘤坏死因子α(TNF)诱导的COX2表达和PGE2产生。噻唑烷二酮类药物罗格列酮(ROSI)和曲格列酮(TRO)对细胞因子诱导的COX2表达影响相对较小,除非在高浓度下,此时这些药物相对于单独用TNF处理的细胞倾向于增加COX2丰度。有趣的是,用ROSI治疗,但不是TRO,导致TNF刺激的PGE2产生增加。从机制上讲,我们观察到15d-PGJ2显著降低了细胞因子诱导的NFκB转录因子活性,而噻唑烷二酮类药物对该系统没有明显影响。我们的数据表明,药理学和内源性PPARG配体使用受体依赖性和非依赖性机制来影响COX2表达。